These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34622175)

  • 21. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity.
    Kim MC; Lee YN; Hwang HS; Lee YT; Ko EJ; Jung YJ; Cho MK; Kim YJ; Lee JS; Ha SH; Kang SM
    Vaccine; 2014 Oct; 32(44):5824-31. PubMed ID: 25171841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge.
    Magini D; Giovani C; Mangiavacchi S; Maccari S; Cecchi R; Ulmer JB; De Gregorio E; Geall AJ; Brazzoli M; Bertholet S
    PLoS One; 2016; 11(8):e0161193. PubMed ID: 27525409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    Walz L; Kays SK; Zimmer G; von Messling V
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.
    Wack A; Baudner BC; Hilbert AK; Manini I; Nuti S; Tavarini S; Scheffczik H; Ugozzoli M; Singh M; Kazzaz J; Montomoli E; Del Giudice G; Rappuoli R; O'Hagan DT
    Vaccine; 2008 Jan; 26(4):552-61. PubMed ID: 18162266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Squalene-containing licensed adjuvants enhance strain-specific antibody responses against the influenza hemagglutinin and induce subtype-specific antibodies against the neuraminidase.
    Schmidt R; Holznagel E; Neumann B; Alex N; Sawatsky B; Enkirch T; Pfeffermann K; Kruip C; von Messling V; Wagner R
    Vaccine; 2016 Oct; 34(44):5329-5335. PubMed ID: 27616472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-protective immunity against influenza A/H1N1 virus challenge in mice immunized with recombinant vaccine expressing HA gene of influenza A/H5N1 virus.
    Yang S; Niu S; Guo Z; Yuan Y; Xue K; Liu S; Jin H
    Virol J; 2013 Sep; 10():291. PubMed ID: 24053449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.
    Kim YJ; Kim KH; Ko EJ; Kim MC; Lee YN; Jung YJ; Lee YT; Kwon YM; Song JM; Kang SM
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30068650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity.
    Hong DK; Chang S; Botham CM; Giffon TD; Fairman J; Lewis DB
    J Virol; 2010 Dec; 84(24):12691-702. PubMed ID: 20943978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection against H5N1 by multiple immunizations with seasonal influenza vaccine in mice is correlated with H5 cross-reactive antibodies.
    Roos A; Roozendaal R; Theeuwsen J; Riahi S; Vaneman J; Tolboom J; Dekking L; Koudstaal W; Goudsmit J; Radošević K
    Vaccine; 2015 Mar; 33(14):1739-47. PubMed ID: 25659276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of Cross-protection by Influenza Virus M2-based Vaccines.
    Lee YN; Kim MC; Lee YT; Kim YJ; Kang SM
    Immune Netw; 2015 Oct; 15(5):213-21. PubMed ID: 26557805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of cross-protective influenza a vaccines based on cellular responses.
    Soema PC; van Riet E; Kersten G; Amorij JP
    Front Immunol; 2015; 6():237. PubMed ID: 26029218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.
    Budimir N; Huckriede A; Meijerhof T; Boon L; Gostick E; Price DA; Wilschut J; de Haan A
    PLoS One; 2012; 7(1):e30898. PubMed ID: 22303469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection.
    Valkenburg SA; Li OT; Mak PW; Mok CK; Nicholls JM; Guan Y; Waldmann TA; Peiris JS; Perera LP; Poon LL
    Proc Natl Acad Sci U S A; 2014 Apr; 111(15):5676-81. PubMed ID: 24706798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection.
    Fonseca DM; Silva CL; Paula MO; Soares EG; Marchal G; Horn C; Bonato VL
    Immunology; 2007 Aug; 121(4):508-17. PubMed ID: 17433075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination Adjuvants Enhance Recombinant Protein Vaccine Protection against Fungal Infection.
    Wüthrich M; Dobson HE; Ledesma Taira C; Okaa UJ; Dos Santos Dias L; Isidoro-Ayza M; Petrovsky N; Klein BS
    mBio; 2021 Aug; 12(4):e0201821. PubMed ID: 34399628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pilot-scale production of inactivated monoglycosylated split H
    Wu CY; Kao SE; Tseng YC; Lin YP; Hou JT; Wu LY; Chiu S; Ma CA; Hsiao PW; Hsiao J; Chen JR
    Antiviral Res; 2023 Aug; 216():105640. PubMed ID: 37263355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models.
    Khodai T; Chappell D; Christy C; Cockle P; Eyles J; Hammond D; Gore K; McCluskie MJ; Evans DM; Lang S; Loudon PT; Townend T; Wright P; West K; Bright H
    Clin Vaccine Immunol; 2011 Oct; 18(10):1702-9. PubMed ID: 21852545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influenza virus-like particles containing M2 induce broadly cross protective immunity.
    Song JM; Wang BZ; Park KM; Van Rooijen N; Quan FS; Kim MC; Jin HT; Pekosz A; Compans RW; Kang SM
    PLoS One; 2011 Jan; 6(1):e14538. PubMed ID: 21267073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.